Comprehensive Tumor Mutational Profiling from Whole Cancer Cells
Unlike ctDNA tests, CellSight™ DNA analyzes intact whole tumor cells (WTC), revealing a richer picture of cancer biology with just one blood draw.
Who We Serve
Patients →
Answers when biopsies aren’t possible. A fast, noninvasive blood test that reveals your cancer’s biology and guides therapy.
Providers →
Whole-cell insights for smarter decisions at diagnosis, relapse, or when tissue is insufficient.
Biopharma →
A next-gen platform for translational research, enabling multiomic insights and patient stratification in precision oncology trials.
Supporting patients, providers, and biopharma with next-generation liquid biopsy solutions designed for diagnosis, therapy selection, and clinical trials.
Why Whole Cells Matter
Unlike ctDNA tests, CellSight™ analyzes intact whole cancer cells. This whole-cell approach preserves tumor context, maintains heterogeneity, and captures phenotypic data—delivering insights that ctDNA alone cannot provide.
CellSight™ DNA
The Future of Liquid Biopsy
CellSight™ DNA combines genomic and phenotypic profiling to deliver a more complete view of tumor biology. Unlike ctDNA tests, it captures intact whole cancer cells—unlocking insights other assays miss.
Whole Cancer Cell Isolation
Capture rare tumor cells with high efficiency, even in low-burden patients, unlocking insights from a simple blood draw.
Genomic Profiling
Turn isolated whole cancer cells into actionable data with RNA-Seq and qPCR, revealing unique biomarkers for precision oncology.
Phenotypic Profiling
Visualize and analyze whole-cell morphology and protein expression to uncover biomarkers beyond DNA, enabling richer biological insights.
Pharma Services
Accelerate discovery with custom assays for biomarker validation, drug resistance, and efficacy testing.
Our Work
At Diagnosis
When tissue is scarce or difficult to obtain, CellSight™ captures intact whole cancer cells from blood to deliver comprehensive genomic profiling. Oncologists receive rapid answers—covering 500+ genes, MSI, and TMB—in just 10-14 days, without the need for surgical biopsy.
At Progression
CellSight™ reveals how cancer evolves over time by detecting resistance mutations in intact whole cancer cells. This approach preserves tumor context and heterogeneity, helping providers identify the next effective therapy while minimizing the need for repeat invasive procedures.
When Tissue Biopsy Isn't Feasible
When tissue biopsy isn’t an option, CellSight™ offers a non-invasive alternative. By analyzing intact whole cancer cells from a simple blood draw, clinicians can access critical genomic and phenotypic insights without the risks of invasive procedures—enabling precision care even when traditional sampling isn’t possible.
At Diagnosis
When tissue is scarce or difficult to obtain, CellSight™ captures intact whole cancer cells from blood to deliver comprehensive genomic profiling. Oncologists receive rapid answers—covering 500+ genes, MSI, and TMB—in just 10-14 days, without the need for surgical biopsy.
At Progression
CellSight™ reveals how cancer evolves over time by detecting resistance mutations in intact whole cancer cells. This approach preserves tumor context and heterogeneity, helping providers identify the next effective therapy while minimizing the need for repeat invasive procedures.
When Tissue Biopsy Isn't Feasible
When tissue biopsy isn’t an option, CellSight™ offers a non-invasive alternative. By analyzing intact whole cancer cells from a simple blood draw, clinicians can access critical genomic and phenotypic insights without the risks of invasive procedures—enabling precision care even when traditional sampling isn’t possible.
From Blood Draw
to Actionable Insights
CellSight™ DNA was designed to be simple, fast, and clinically meaningful. Here’s how we turn a single blood sample into clarity for patients, providers, and pharma partners:
Sample Collection
Just 10 mL of blood, no surgery required.
Whole Cancer Cell Isolation
Intact whole cancer cells are captured with our proprietary platform.
Genomic Profiling
500+ cancer-related genes, MSI, and TMB analyzed with next-gen sequencing.
Phenotypic Insights
Tumor context and heterogeneity preserved for a fuller picture.
Reporting
Clear, structured results delivered in just 10-14 days.
Next Steps
Actionable insights guide therapy selection, monitoring, or trial integration.